Enamine's IDD Platform Boosts ABX-CRO's Translational Medicine Approach towards Imaging Agents and Radiopharmaceuticals
KYIV, UKRAINE, January 16, 2026 /EINPresswire.com/ -- ABX-CRO and Enamine initiated their cooperation in 2024. Since then, Enamine supports ABX-CRO with its integrated competencies in biology, chemistry, and computational sciences through its research centers in Frankfurt/Germany, Kyiv/Ukraine, and Wroclaw/Poland. The initial relationship proved to be highly productive, securing innovation in short research cycles and utilizing resources at its highest return on investment. In consequence of this success, ABX-CRO and Enamine continue to deepen their relationship for the future.
Enamineโs profound knowledge of chemical space, namely with its REAL compounds, the worldโs largest collection of make-on-demand small molecules that represents a significant fraction of such synthetically accessible chemical space. Its member molecules are REadily AccessibLe through validated parallel synthesis protocols using qualified in-stock building blocks.
In combination with its expanded capabilities in medicinal chemistry and computer-aided drug design, and its optimized research logistics, Enamine accomplishes design-make-test-analyze cycles of small molecules in drug discovery within days rather than weeks. Enamine Germany in Frankfurt enables support of rapid lead optimization and project management. Enamine's capabilities in biology, from hit identification, lead optimization, and translating into preclinical proof-of-concept studies, are critically supported by its biology research centers in Kyiv and Wroclaw through their high-throughput screening, in vitro ADME, and in vivo PK/Tox, and other biological capabilities.
๐๐ง๐๐ซ๐๐๐ฌ ๐ ๐ข๐ง๐ญ๐๐ฅ๐ฆ๐๐ง๐ง, ๐๐๐ง๐๐ ๐ข๐ง๐ ๐๐ข๐ซ๐๐๐ญ๐จ๐ซ ๐จ๐ ๐๐๐-๐๐๐: "๐๐ฆ ๐ข๐ณ๐ฆ ๐จ๐ญ๐ข๐ฅ ๐ข๐ฏ๐ฅ ๐ฉ๐ฐ๐ฏ๐ฐ๐ณ๐ฆ๐ฅ ๐ต๐ฐ ๐ค๐ฐ๐ฏ๐ต๐ช๐ฏ๐ถ๐ฆ ๐ฐ๐ถ๐ณ ๐ธ๐ฐ๐ณ๐ฌ ๐ข๐ฏ๐ฅ ๐ค๐ฐ๐ญ๐ญ๐ข๐ฃ๐ฐ๐ณ๐ข๐ต๐ช๐ฐ๐ฏ ๐ธ๐ช๐ต๐ฉ ๐๐ฏ๐ข๐ฎ๐ช๐ฏ๐ฆ ๐๐ฆ๐ณ๐ฎ๐ข๐ฏ๐บ, ๐ข๐ด ๐ธ๐ฆ๐ญ๐ญ ๐ข๐ด ๐๐ฏ๐ข๐ฎ๐ช๐ฏ๐ฆ ๐๐ฌ๐ณ๐ข๐ช๐ฏ๐ฆ ๐ข๐ฏ๐ฅ ๐๐ฐ๐ญ๐ข๐ฏ๐ฅ, ๐ข๐ด ๐ช๐ฎ๐ฑ๐ฐ๐ณ๐ต๐ข๐ฏ๐ต ๐ฌ๐ฆ๐บ ๐ฑ๐ข๐ณ๐ต๐ฏ๐ฆ๐ณ๐ด ๐ฐ๐ง ๐๐๐-๐๐๐. ๐๐ฉ๐ฆ ๐ง๐ญ๐ฆ๐น๐ช๐ฃ๐ช๐ญ๐ช๐ต๐บ ๐ข๐ฏ๐ฅ ๐ฑ๐ณ๐ฐ๐ฅ๐ถ๐ค๐ต๐ช๐ท๐ฆ ๐ฐ๐ถ๐ต๐ฑ๐ถ๐ต ๐ข๐ณ๐ฆ ๐ช๐ฎ๐ฑ๐ณ๐ฆ๐ด๐ด๐ช๐ท๐ฆ, ๐ข๐ฏ๐ฅ ๐ต๐ฉ๐ฆ ๐๐ฏ๐ข๐ฎ๐ช๐ฏ๐ฆ ๐ต๐ฆ๐ข๐ฎ ๐ช๐ด ๐ท๐ฆ๐ณ๐บ ๐ค๐ฐ๐ฎ๐ฑ๐ฆ๐ต๐ฆ๐ฏ๐ต, ๐ฉ๐ช๐จ๐ฉ๐ญ๐บ ๐ณ๐ฆ๐ด๐ฑ๐ฐ๐ฏ๐ด๐ช๐ท๐ฆ, ๐ข๐ฏ๐ฅ ๐ฑ๐ณ๐ฐ๐ง๐ฆ๐ด๐ด๐ช๐ฐ๐ฏ๐ข๐ญ. ๐๐ณ๐ฐ๐ซ๐ฆ๐ค๐ต ๐ฅ๐ฆ๐ข๐ฅ๐ญ๐ช๐ฏ๐ฆ๐ด ๐ธ๐ฆ๐ณ๐ฆ ๐ข๐ญ๐ธ๐ข๐บ๐ด ๐ฎ๐ฆ๐ต, ๐ข๐ฏ๐ฅ ๐ธ๐ฆ ๐ฆ๐น๐ฑ๐ฆ๐ณ๐ช๐ฆ๐ฏ๐ค๐ฆ๐ฅ ๐ฆ๐น๐ค๐ฆ๐ญ๐ญ๐ฆ๐ฏ๐ต ๐ฑ๐ณ๐ฐ๐ซ๐ฆ๐ค๐ต ๐ฎ๐ข๐ฏ๐ข๐จ๐ฆ๐ฎ๐ฆ๐ฏ๐ต ๐ข๐ฏ๐ฅ ๐ณ๐ฆ๐ฑ๐ฐ๐ณ๐ต๐ช๐ฏ๐จ ๐ฐ๐ท๐ฆ๐ณ๐ข๐ญ๐ญ. ๐๐ฉ๐ช๐ด ๐ฐ๐ถ๐ต๐ด๐ต๐ข๐ฏ๐ฅ๐ช๐ฏ๐จ ๐ด๐ค๐ช๐ฆ๐ฏ๐ต๐ช๐ง๐ช๐ค ๐ง๐ฐ๐ค๐ถ๐ด ๐ฐ๐ง ๐๐ฏ๐ข๐ฎ๐ช๐ฏ๐ฆ ๐ช๐ด ๐ฑ๐ฐ๐ด๐ด๐ช๐ฃ๐ญ๐ฆ ๐ฃ๐ฆ๐ค๐ข๐ถ๐ด๐ฆ ๐ฐ๐ง ๐ช๐ต๐ด ๐ถ๐ฏ๐ช๐ฒ๐ถ๐ฆ ๐ช๐ฏ๐ต๐ฆ๐จ๐ณ๐ข๐ต๐ฆ๐ฅ ๐ฅ๐ณ๐ถ๐จ ๐ฅ๐ช๐ด๐ค๐ฐ๐ท๐ฆ๐ณ๐บ (๐๐๐) ๐ฑ๐ญ๐ข๐ต๐ง๐ฐ๐ณ๐ฎ. ๐๐ฉ๐ฆ ๐๐ฏ๐ข๐ฎ๐ช๐ฏ๐ฆ ๐ค๐ฐ๐ญ๐ญ๐ฆ๐ข๐จ๐ถ๐ฆ๐ด ๐ข๐ณ๐ฆ ๐ข๐ฃ๐ญ๐ฆ ๐ต๐ฐ ๐ง๐ข๐ค๐ช๐ญ๐ช๐ต๐ข๐ต๐ฆ ๐ฒ๐ถ๐ช๐ค๐ฌ ๐ณ๐ฐ๐ถ๐ต๐ฆ ๐ด๐ค๐ฐ๐ถ๐ต๐ช๐ฏ๐จ ๐ข๐ฏ๐ฅ ๐ถ๐ฑ๐ด๐ค๐ข๐ญ๐ช๐ฏ๐จ ๐ต๐ฐ ๐ฉ๐ช๐จ๐ฉ ๐ฒ๐ถ๐ข๐ญ๐ช๐ต๐บ ๐ถ๐ฏ๐ฅ๐ฆ๐ณ ๐ต๐ช๐ฎ๐ฆ ๐ฑ๐ณ๐ฆ๐ด๐ด๐ถ๐ณ๐ฆ ๐ข๐ฏ๐ฅ ๐ช๐ฏ ๐ฒ๐ถ๐ข๐ฏ๐ต๐ช๐ต๐ช๐ฆ๐ด ๐ฆ๐ฏ๐ข๐ฃ๐ญ๐ช๐ฏ๐จ ๐ช๐ฏ ๐ท๐ช๐ท๐ฐ ๐ด๐ต๐ถ๐ฅ๐ช๐ฆ๐ด. ๐๐ฏ๐ข๐ฎ๐ช๐ฏ๐ฆ'๐ด ๐ช๐ฎ๐ฑ๐ณ๐ฆ๐ด๐ด๐ช๐ท๐ฆ ๐ฃ๐ช๐ฐ๐ญ๐ฐ๐จ๐ช๐ค๐ข๐ญ ๐ค๐ข๐ฑ๐ข๐ค๐ช๐ต๐ช๐ฆ๐ด ๐ข๐ณ๐ฆ ๐ถ๐ด๐ฆ๐ฅ ๐ข๐ฏ๐ฅ ๐ฉ๐ช๐จ๐ฉ๐ญ๐บ ๐ข๐ฑ๐ฑ๐ณ๐ฆ๐ค๐ช๐ข๐ต๐ฆ๐ฅ ๐ฃ๐บ ๐ถ๐ด ๐ง๐ฐ๐ณ ๐ช๐ฏ ๐ท๐ช๐ท๐ฐ ๐ด๐ต๐ถ๐ฅ๐ช๐ฆ๐ด, ๐ต๐ฐ๐ฐ."
๐๐ฏ๐๐ง ๐๐๐ ๐ง๐๐ซ, ๐๐ก๐, ๐๐ข๐๐ ๐๐ซ๐๐ฌ๐ข๐๐๐ง๐ญ ๐จ๐ ๐๐๐ซ๐ญ๐ง๐๐ซ๐ฌ๐ก๐ข๐ฉ๐ฌ ๐๐ญ ๐๐ง๐๐ฆ๐ข๐ง๐: "๐๐ฆ ๐ข๐ณ๐ฆ ๐ฑ๐ญ๐ฆ๐ข๐ด๐ฆ๐ฅ ๐ต๐ฐ ๐ฆ๐น๐ฑ๐ข๐ฏ๐ฅ ๐ฐ๐ถ๐ณ ๐ฑ๐ข๐ณ๐ต๐ฏ๐ฆ๐ณ๐ด๐ฉ๐ช๐ฑ ๐ธ๐ช๐ต๐ฉ ๐๐๐-๐๐๐ ๐ข๐ฏ๐ฅ ๐ต๐ฉ๐ฆ ๐ณ๐ข๐ฅ๐ช๐ฐ๐ฑ๐ฉ๐ข๐ณ๐ฎ๐ข-๐ค๐ญ๐ถ๐ด๐ต๐ฆ๐ณ ๐ช๐ฏ ๐๐ข๐น๐ฐ๐ฏ๐บ, ๐๐ฆ๐ณ๐ฎ๐ข๐ฏ๐บ ๐ฃ๐บ ๐ด๐ถ๐ฑ๐ฑ๐ฐ๐ณ๐ต๐ช๐ฏ๐จ ๐ต๐ฉ๐ฆ๐ช๐ณ ๐ค๐ถ๐ต๐ต๐ช๐ฏ๐จ-๐ฆ๐ฅ๐จ๐ฆ ๐ข๐ฑ๐ฑ๐ณ๐ฐ๐ข๐ค๐ฉ ๐ช๐ฏ ๐ฑ๐ณ๐ฆ๐ค๐ญ๐ช๐ฏ๐ช๐ค๐ข๐ญ ๐ฑ๐ณ๐ฐ๐ฐ๐ง-๐ฐ๐ง-๐ค๐ฐ๐ฏ๐ค๐ฆ๐ฑ๐ต ๐ณ๐ฆ๐ด๐ฆ๐ข๐ณ๐ค๐ฉ ๐ง๐ฐ๐ณ ๐ฏ๐ถ๐ค๐ญ๐ฆ๐ข๐ณ ๐ฎ๐ฆ๐ฅ๐ช๐ค๐ช๐ฏ๐ฆ ๐ข๐ฏ๐ฅ ๐ต๐ฉ๐ฆ๐ณ๐ข๐ฏ๐ฐ๐ด๐ต๐ช๐ค๐ด. ๐๐ฐ๐จ๐ฆ๐ต๐ฉ๐ฆ๐ณ, ๐ธ๐ฆ ๐ฉ๐ข๐ท๐ฆ ๐ข ๐ฑ๐ณ๐ฐ๐ท๐ฆ๐ฏ, ๐ฆ๐น๐ค๐ฆ๐ฑ๐ต๐ช๐ฐ๐ฏ๐ข๐ญ, ๐ช๐ฏ๐ฏ๐ฐ๐ท๐ข๐ต๐ช๐ท๐ฆ, ๐ข๐ฏ๐ฅ ๐ข๐จ๐ช๐ญ๐ฆ ๐ต๐ฆ๐ข๐ฎ ๐ฐ๐ง ๐ฆ๐น๐ฑ๐ฆ๐ณ๐ต๐ด ๐ด๐ถ๐ฑ๐ฑ๐ฐ๐ณ๐ต๐ช๐ฏ๐จ ๐ต๐ฉ๐ฆ ๐ฉ๐ช๐จ๐ฉ๐ญ๐บ ๐ฑ๐ข๐ต๐ช๐ฆ๐ฏ๐ต-๐ค๐ฆ๐ฏ๐ต๐ณ๐ช๐ค ๐ง๐ฐ๐ค๐ถ๐ด ๐ฐ๐ง ๐๐๐-๐๐๐, ๐ข๐ฅ๐ท๐ข๐ฏ๐ค๐ช๐ฏ๐จ ๐ฎ๐ฆ๐ฅ๐ช๐ค๐ข๐ญ ๐ฑ๐ณ๐ฐ๐จ๐ณ๐ฆ๐ด๐ด ๐ช๐ฏ ๐ฏ๐ถ๐ค๐ญ๐ฆ๐ข๐ณ ๐ฎ๐ฆ๐ฅ๐ช๐ค๐ช๐ฏ๐ฆ ๐ธ๐ช๐ต๐ฉ๐ฐ๐ถ๐ต ๐ฅ๐ฆ๐ญ๐ข๐บ."
Company Summaries:
๐๐๐จ๐ฎ๐ญ ๐๐๐-๐๐๐
ABX-CRO is specialised in the field of pre-clinical and clinical contract research involving functional imaging methodologies with emphasis on molecular imaging with PET and SPECT. Study design, placement, regulatory set-up, project management, clinical monitoring as well as technical quality assurance of imaging devices, collection, handling, analysis and reporting of image data is within the scope of its current activities, as well as the development of own pharmaceutical drug candidates.
For more information, please visit: www.abx-cro.com
๐๐๐จ๐ฎ๐ญ ๐๐ง๐๐ฆ๐ข๐ง๐
Enamine is the leading provider of chemical compounds and a scientifically driven, integrated discovery Contract Research Organisation for integrated discovery with unique partnering opportunities in exploring new chemical space. The company combines access to the in-house produced screening compounds (4.5 million in stock) and building blocks (350,000 in stock) with a comprehensive platform of integrated discovery services in bioinformatics, biology, and chemistry to advance and accelerate the efforts in drug discovery.
For more information, please visit: enamine.net/
Contact Information
๐
๐จ๐ซ ๐๐๐-๐๐๐ ๐๐๐ฏ๐๐ง๐๐๐ ๐ฉ๐ก๐๐ซ๐ฆ๐๐๐๐ฎ๐ญ๐ข๐๐๐ฅ ๐ฌ๐๐ซ๐ฏ๐ข๐๐๐ฌ
๐
๐จ๐ซ๐ฌ๐๐ก๐ฎ๐ง๐ ๐ฌ๐ ๐๐ฌ๐๐ฅ๐ฅ๐ฌ๐๐ก๐๐๐ญ ๐ฆ๐๐:
Andreas Fintelmann
Managing Director
Phone: +49 151 4256 3498
Email: andreas.fintelmann@abx-cro.com
๐
๐จ๐ซ ๐๐ง๐๐ฆ๐ข๐ง๐:
Yurii Moroz, DSc.
Vice President of Sales and Marketing
Email: y.moroz@enamine.net
Dr. Yurii Moroz
Enamine Ltd.
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
